Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Holding INCY?
Track your performance easily
INCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.35 - $76.33
Previous Close$76.13
Volume1.46M
Average Volume (3M)1.82M
Market Cap
$14.67B
Enterprise Value$12.92B
Total Cash (Recent Filing)$1.77B
Total Debt (Recent Filing)$32.16M
Price to Earnings (P/E)539.2
Beta0.64
Next Earnings
Feb 13, 2025EPS Estimate
$1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding192,650,249
10 Day Avg. Volume1,847,109
30 Day Avg. Volume1,817,720
Standard Deviation0.08
R-Squared0.19
Alpha-0.00715
Financial Highlights & Ratios
Price to Book (P/B)4.63
Price to Sales (P/S)3.60
Price to Cash Flow (P/CF)11.80
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda35.67
Forecast
1Y Price Target
$76.65Price Target Upside1.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Incyte News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJakafi net product revenues exceeded expectations, coming in at $741 million versus the consensus of $715 million.
Future ProspectsThe company expects three near-term launches that could reach over $800 million in incremental revenues by 2029.
Pipeline DevelopmentManagement has finalized the Phase 3 design of ruxolitinib cream in hidradenitis suppurativa, aiming for a more stringent endpoint to reduce the risk of missing efficacy.
Bears Say
Financial PerformanceNet income of ~$106mn and EPS of $0.55 missed consensus estimates of ~$150mn and ~$0.84, likely due to higher expense from fair value of contingent consideration.
Future Revenue ConcernsIncyte is facing a major revenue cliff starting early 2029 due to the entry of generics threatening Jakafi revenue.
Revenue GrowthJakafi growth continues to slow despite indication expansion in PV and GVHD.
---
Ownership Overview
15.65% Insiders
23.45% Mutual Funds
2.32% Other Institutional Investors
33.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $50.35 and its highest was $76.33 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Feb 13, 2025 which is in 100 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Oct 29, 2024. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $1.051 by $0.019.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is $1.5.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 192,650,250 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.07 in its last earnings report, beating expectations of $1.051. Following the earnings report the stock price went up 12.041%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$76.65 (1.19% Upside)
$76.65 (1.19% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 91%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 6.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.02%
12-Months-Change
Fundamentals
Return on Equity
0.80%
Trailing 12-Months
Asset Growth
-21.54%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q3 2024
0:00 / 0:00
---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Month Forecast
Average Price Target
$76.65
▲(1.19% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+12.81%
reiterated a buy rating 7 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +12.81% per trade.
---